1. Home
  2. NKTX vs GLU Comparison

NKTX vs GLU Comparison

Compare NKTX & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTX
  • GLU
  • Stock Information
  • Founded
  • NKTX 2015
  • GLU 2004
  • Country
  • NKTX United States
  • GLU United States
  • Employees
  • NKTX N/A
  • GLU N/A
  • Industry
  • NKTX Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • NKTX Health Care
  • GLU Finance
  • Exchange
  • NKTX Nasdaq
  • GLU Nasdaq
  • Market Cap
  • NKTX 123.5M
  • GLU 99.4M
  • IPO Year
  • NKTX 2020
  • GLU N/A
  • Fundamental
  • Price
  • NKTX $1.80
  • GLU $17.65
  • Analyst Decision
  • NKTX Strong Buy
  • GLU
  • Analyst Count
  • NKTX 6
  • GLU 0
  • Target Price
  • NKTX $14.40
  • GLU N/A
  • AVG Volume (30 Days)
  • NKTX 434.5K
  • GLU 12.4K
  • Earning Date
  • NKTX 08-12-2025
  • GLU 01-01-0001
  • Dividend Yield
  • NKTX N/A
  • GLU 8.60%
  • EPS Growth
  • NKTX N/A
  • GLU N/A
  • EPS
  • NKTX N/A
  • GLU 0.62
  • Revenue
  • NKTX N/A
  • GLU N/A
  • Revenue This Year
  • NKTX N/A
  • GLU N/A
  • Revenue Next Year
  • NKTX N/A
  • GLU N/A
  • P/E Ratio
  • NKTX N/A
  • GLU $22.50
  • Revenue Growth
  • NKTX N/A
  • GLU N/A
  • 52 Week Low
  • NKTX $1.31
  • GLU $11.61
  • 52 Week High
  • NKTX $8.23
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • NKTX 51.45
  • GLU 68.62
  • Support Level
  • NKTX $1.68
  • GLU $17.38
  • Resistance Level
  • NKTX $1.84
  • GLU $17.77
  • Average True Range (ATR)
  • NKTX 0.08
  • GLU 0.20
  • MACD
  • NKTX 0.01
  • GLU 0.05
  • Stochastic Oscillator
  • NKTX 80.95
  • GLU 100.00

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: